AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00797108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone and amoxicillin/clavulanate
Description: IV ceftriaxone (2g) infused over 30 minutes QD (once daily) for minimum of 2 days Step down oral amoxicillin/clavulanate potassium suspension (400 mg/5 ml) BID (every 12 hours)
Study NCT03194464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: submaximal exercise (grip)
Description: participants perform repeated gripping with visual feedback to task failure
Study NCT02538445 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Memorization of the verbs by miming the action
Description: The participant reads aloud the verbs that appear on the screen, by performing the corresponding action verb.
Study NCT02538445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Memorization of the verbs by miming the action
Description: The participant reads aloud the verbs that appear on the screen, by performing the corresponding action verb.
Study NCT02538445 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Memorization of the verbs by imagining the action
Description: The participant reads aloud the verbs that appear on the screen, by imagining the corresponding action verb.
Study NCT02538445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Memorization of the verbs by imagining the action
Description: The participant reads aloud the verbs that appear on the screen, by imagining the corresponding action verb.
Study NCT02538445 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Memorization of the action verbs by means of another word
Description: The participant reads aloud the verbs that appear on the screen. Then, he reads, without memorizing it, a word associated with the action verb to be learnt to favor the memorization of that one. The word is written near the action verb.
Study NCT02538445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Memorization of the action verbs by means of another word
Description: The participant reads aloud the verbs that appear on the screen. Then, he reads, without memorizing it, a word associated with the action verb to be learnt to favor the memorization of that one. The word is written near the action verb.
Study NCT02538445 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simple memorization of the verbs
Description: The participant reads aloud the verbs that appear on the screen, without additional instructions (control condition).
Study NCT02538445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simple memorization of the verbs
Description: The participant reads aloud the verbs that appear on the screen, without additional instructions (control condition).
Study NCT02464566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Study NCT02464566 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Study NCT02464566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Education
Study NCT01932840 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mock package questionnaire
Description: Within a online questionnaire we exposed participants randomly to 4 mock margarine packages differing only by the claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
Study NCT00117949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
Study NCT00117949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
Study NCT00117949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
Study NCT00117949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
Study NCT01502943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Louxiangdan Tongxin granules
Description: TCM treatment:~Decoction: Louxiangdan Tongxin granules Herbs:Danshen 10g、Chenxiang 1g、Gualou10g、Xiebai 10g、Banxia6g、Chuanxiong 6g 、Dangshen 10g、Zhiqiao 6g、Taoren 10g、Guizhi 6g Therapeutic Principle:Invigorating Spleen to Remove Phlegm and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.~Usage:Once 100ml, twice per day after breakfast and supper.
Study NCT01502943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TCM granules placebo
Description: Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
Study NCT01502943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chixiangshen Tongxin granules
Description: TCM treatment:~Decoction: Chixiangshen Tongxin granules Herbs: Chishao 10g, Chenxiang 1g, Danggui 10g, Jupi 10g, Yanhusuo 6g, Chuanxiong 6g, Dangshen 10g, Huangqi 6g, Taoren 10g, Honghua 10g Therapeutic Principle:Invigorating Spleen to Replenish Qi and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.~Usage:Once 100ml, twice per day after breakfast and supper.
Study NCT01502943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TCM granule placebo plus western basis treatment
Description: Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
Study NCT01502943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Western basis treatment
Description: Aspirin: 100mg pd. P.O.( patients who have Aspirin resistance or Allergy can replaced with Piece clopidogrel 75mg pd. P.O.) Atorvastatin calcium (Lipitor): 10mg pd. P.O.( patients who have Atorvastatin calcium resistance or Allergy can replaced with Additive amount of pravastatin equal to 10mg Lipitor) Nitroglycerin: sublingual necessary.
Study NCT01502943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Western basis treatment
Description: Aspirin: 100mg pd. P.O.( patients who have Aspirin resistance or Allergy can replaced with Piece clopidogrel 75mg pd. P.O.) Atorvastatin calcium (Lipitor): 10mg pd. P.O.( patients who have Atorvastatin calcium resistance or Allergy can replaced with Additive amount of pravastatin equal to 10mg Lipitor) Nitroglycerin: sublingual necessary.
Study NCT02636816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbetocin
Description: drug used to increase the tone of uterine muscle to prevent post partum hemorrhage after cesarean delivery.
Study NCT02636816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbetocin
Description: drug used to increase the tone of uterine muscle to prevent post partum hemorrhage after cesarean delivery.
Study NCT04260503 — intervention group
Intervention type: OTHER
Intervention: Monitoring of the gut-microbiome and ultrasound elasticity.
Description: The investigator will investigate the alteration of gut-microbiome and liver stiffness by restoration of bile flow by operation.
Study NCT04260503 — intervention group
Intervention type: OTHER
Intervention: Monitoring of the gut-microbiome
Description: The investigator will investigate the alteration of gut-microbiome before and after operation.
Study NCT04260503 — intervention group
Intervention type: OTHER
Intervention: Monitoring of the gut-microbiome
Description: The investigator will investigate the alteration of gut-microbiome along with the disease progress.
Study NCT04260503 — intervention group
Intervention type: OTHER
Intervention: Monitoring of the gut-microbiome.
Description: The investigator will investigate the alteration of gut-microbiome according to the normal development.
Study NCT03221374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: 8-week mindfulness based stress reduction course intended to develop mind-body awareness through mindfulness practices.
Study NCT03048162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride
Description: 500 ml of 0.9% isotonic sodium chloride
Study NCT03048162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyethylstarch
Description: 500 ml of 6% Hydroxyethylstarch
Study NCT03048162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer-Lactate Infusion Solution Bag
Description: 500 ml of Ringer-Lactate Infusion Solution Bag
Study NCT04090892 — intervention group
Intervention type: PROCEDURE
Intervention: selective percutaneous muscle release
Description: Children will be evaluated before and two times after they undergo a selective percutaneous myofascial release. Investigators make no determination about the need for the surgery or which muscles are released, nor do they participate in the surgery. The investigators are assess outcomes on gait and motor function.
Study NCT01973049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study NCT01973049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir
Study NCT01973049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Study NCT01973049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study NCT01973049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Ribavirin
Study NCT02567968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg). The time to wake will be measured.
Study NCT02567968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Anesthetized volunteers will be allowed to wake after injection of saline (placebo control). The time to wake will be measured.
Study NCT02016170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180mg
Description: After providing written informed consent, eligible patients on maintenance prasugrel meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily maintenance dose for 7±2 days
Study NCT02016170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel 10mg
Description: After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days
Study NCT02016170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg
Description: After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days
Study NCT00582400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Trisenox will be diluted with 100 to 250 mL 0.9% Sodium Chloride injection, USP, using proper aseptic technique, immediately after withdrawal from the ampule. The Trisenox ampule is single-use and does not contain any preservatives. Unused portions of each ampule should be discarded properly. Trisenox is not to be mixed with other medications.~The loading dose of Trisenox will be administered intravenously over 2 hours. The infusion duration may be extended up to 4 hours if acute vasomotor reactions are observed. The drug will be administered IV through a functional peripheral or central venous line. Trisenox is not a vesicant, and may be a mild irritant if administered into the skin without dilution.
Study NCT03660839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artefenomel (OZ439)
Description: Pharmaceutical form: Granules for oral suspension Route of administration: Oral
Study NCT03660839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferroquine (SSR97193)
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study NCT02979353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shed-Meds: A Patient-Centered Deprescribing Intervention
Description: The goal of the intervention is to safely deprescribe medications, as defined by dose reductions and stopped medications, based on a combination of clinical criteria and patient preferences.
Study NCT00208286 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PFC Sigma Fixed Bearing
Description: PFC Sigma Fixed Bearing system for use in total knee arthroplasty
Study NCT00208286 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFC Sigma Mobile Bearing
Description: PFC Sigma Mobile Bearing system for use in total knee arthroplasty
Study NCT01395186 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: varicocelectomy
Description: varicocelectomy for painful varicocele
Study NCT02161965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: 20mg or 15mg
Study NCT02161965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluindione
Study NCT02161965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study NCT01582607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine plain
Description: 2.0 mL (10mg) plain bupivacaine hydrochloride 0.5% intrathecally
Study NCT01582607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine plain
Description: 2.0 ml (15mg) plain ropivacaine 0.75% intrathecally
Study NCT01582607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine plain
Description: 2.0 ml (10mg) plain levo-bupivacaine hydrochloride 0.5% intrathecally
Study NCT01582607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine plain +fentanyl
Description: 2.0 ml (10mg) plain bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally
Study NCT01582607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine plain +. fentanyl
Description: 2.0 ml (15mg) plain ropivacaine 0.75% with 0.2 ml (10 μg) fentanyl intrathecally
Study NCT01582607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine plain +fentanyl
Description: 2.0 ml (10mg) plain levo-bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally
Study NCT03505853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givosiran
Description: single dose of givosiran by subcutaneous (sc) injection
Study NCT03505853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-probe cocktail
Description: includes midazolam, caffeine, losartan, omeprazole, and dextromethorphan
Study NCT00718679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVN201
Description: Intralymphativ injection of the study drug
Study NCT00718679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01856088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiron Stent
Description: stent implantation
Study NCT01856088 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biomatrix Flex Stent
Description: stent implantation
Study NCT03441581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eluxadoline
Description: Eluxadoline 100 mg oral tablets BID with food.
Study NCT03416764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EFP-NF training
Description: Experimental groups (among participants with and without steady menstrual cycle) will receive a total of 10 training sessions during 10 weeks. In addition to EFP-NF training, participants in the experimental groups will continue to be treated as usual at Clinic for Sexual Assault.
Study NCT02115906 — intervention group
Intervention type: OTHER
Intervention: 1H/31P Magnetic Resonance Spectroscopy
Description: The 31P-MRS examinations will be performed in a 7 T MR system (Siemens Healthcare, Erlangen, Germany) using a double-tuned (31P/1H) surface coil (Rapid Biomedical Ltd, Rimpar, Germany), with a diameter of 10 cm. Participants will be investigated lying in lateral position with the right lobe of the liver positioned over the coil.
Study NCT02115906 — intervention group
Intervention type: OTHER
Intervention: oral glucose tolerance testing
Description: In patients without overt diabetes, glucose tolerance will be assessed by an oral glucose tolerance test, routinely performed at the outpatients clinic. The test will be performed in the morning after an overnight fast of at least 8 hours. Blood will be drawn via a catheter placed in an antecubital vein of one arm. Blood samples for the assessment of glucose, insulin, C-peptide, free fatty acids and growth hormone will be drawn at baseline as well as 30, 60, 90 and 120 minutes after ingestion of 75g glucose in a solution.~Concentrations of glucose, insulin and C-peptide will be used to derive parameters of insulin secretion and insulin sensitivity by mathematical modelling.
Study NCT02115906 — intervention group
Intervention type: OTHER
Intervention: Thyroid sonography
Description: In acromegalic patients thyroid morphology will be assessed at the outpatient clinic of the Division of Endocrinology and Metabolism, using standard ultrasound technique. Measurements will be performed by a well- experienced physician at baseline and at each follow up examination in an out-patient care setting.
Study NCT03311646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal nicotine content cigarettes (NNC, Baseline)
Description: Participants will exclusively smoke research cigarettes that have a normal nicotine content for five days/four nights while staying in a hotel.
Study NCT03311646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC)
Description: Participants will exclusively smoke research cigarettes that have a very low nicotine content for five days/four nights while staying in a hotel.
Study NCT00940368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Provision of capsules containing ginger powder or placebo
Description: The patients(children and adolescents) will be provided with Capsules containing either ginger powder or placebo on the three days when they receive chemotherapy.~For weight category 1(20-40kg),6 capsules are given in three divided doses and the amount of ginger powder administered per day is 1 gram.~For weight category 2(40-60kg), 5 capsules are given in three divided doses and the amount of ginger powder administered per day is 2 gram.
Study NCT00940368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Provision of capsules containing ginger powder or placebo
Description: The patients(children and adolescents) will be provided with Capsules containing either ginger powder or placebo on the three days when they receive chemotherapy.~For weight category 1(20-40kg),6 capsules are given in three divided doses and the amount of ginger powder administered per day is 1 gram.~For weight category 2(40-60kg), 5 capsules are given in three divided doses and the amount of ginger powder administered per day is 2 gram.
Study NCT03858257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen
Description: The Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand) will be used.
Study NCT03858257 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard oxygenation
Description: Supplemental oxygen through a facemask.
Study NCT01989091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B-Lock
Description: Antimicrobial Catheter Lock Solution
Study NCT01989091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin 5,000 U/mL
Description: Standard of Care Catheter Lock Solution
Study NCT03180866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luma Light System
Description: The Luma Light System combines a NBUVB light with an occlusive dressing.
Study NCT04051242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XenMatrix™ AB Surgical Graft
Description: Graft implantation, radiographic, functional, and electrophysotherapy outcomes will be measured at various time points up to 24-28 weeks post-operatively. A CT scan or MRI will be collected at screening and pre-operative visits to evaluate tissue volume, then again at post-operative Visit 1 and Visit 6. Physical therapy training will be performed as a research procedure following Graft implantation for a maximum of 30 weeks. Additionally, Physical Therapy evaluations will be conducted at screening, pre-op visit 1, post-op, and at post-op Visits 3, and 4. A small core needle biopsy 1-5 grams will be collected at three time points to conduct histomorphological assessment of the tissue prior to Graft implantation (Operative visit, Visit 2 and at Visit 4).
Study NCT02141256 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein enriched products
Description: Newly developed products with extra protein. Specially developed for elderly.
Study NCT02716025 — intervention group
Intervention type: PROCEDURE
Intervention: Upper gastrointestinal endoscopy
Description: Thorough examination of the esophagus, stomach and duodenum to the second part was done to all patients using Olympus CV-150 or Pentax EPM-3500.